Skip to content

Intravenous Acetaminophen for Craniotomy Patients

Intravenous Acetaminophen for Craniotomy Patients: A Single-blinded, Randomized Controlled Trial to Evaluate the Effect of Intravenous Acetaminophen Administered at Induction and Emergence From Craniotomy

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01474304
Acronym
IVAC
Enrollment
80
Registered
2011-11-18
Start date
2011-11-30
Completion date
Unknown
Last updated
2016-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Craniotomy

Keywords

craniotomy, tumor resection, aneurysm, revascularization, opioid, nausea, vomiting, acetaminophen

Brief summary

Adding intraoperative IV acetaminophen, in addition to standard analgesics, will decrease opioid requirements over the first 12 hours of postoperative recovery following craniotomy. Opioids exacerbate symptoms of nausea and vomiting. Reducing postoperative opioid use hopefully will reduce incidence of nausea and vomiting in patients after craniotomy.

Interventions

DRUGAcetaminophen

1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery

Sponsors

Mallinckrodt
CollaboratorINDUSTRY
Swedish Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 years of age * Weigh at least 50 kg (110.23 lbs) * Undergoing open, elective intracranial procedure for * tumor resection * aneurysm clipping * revascularization * Have an ASA (American Society of Anesthesiologists) physical status of 1, 2, 3, or 4 * Able to provide written informed consent

Exclusion criteria

* Significant medical disease, laboratory abnormality, or condition that, in the opinion of the investigator, would compromise patient welfare or would otherwise contraindicate study participation * Unable to communicate symptoms * Current daily opioid use (\>40 mg morphine equivalent) * Tramadol use * Treated with MAO (monoamine oxidase inhibitors) inhibitors within 10 days of surgery * Treated with any amount of acetaminophen within 8 hours of anesthesia for surgery * Allergic or hypersensitive to acetaminophen or any contraindications per manufacturer's guidelines * Pregnancy * Impaired liver function * Participation in interventional clinical study within the last 30 days * Known or suspected history of alcohol or drug abuse * Surgery for resection of acoustic neuroma * Transphenoidal tumor resection

Design outcomes

Primary

MeasureTime frameDescription
Total narcotic dose administered over the first 12 hours of postoperative recovery.12 hoursIntensive care nurses will ask subject about pain and nausea every 15 minutes for the first two hours immediately after surgery and then every hour afterward for up to 12 hours. Nurses will record subject response and opioid doses given.

Secondary

MeasureTime frame
Incidence of nausea during postoperative recovery12 hours
Incidence of vomiting during postoperative recovery12 hours
Severity of nausea during postoperative recovery12 hours
Severity of vomiting during postoperative recovery12 hours

Countries

United States

Contacts

Primary ContactBecky Wood
becky.wood@swedish.org206-320-7115
Backup ContactNathan Hansen
nathan.hansen@swedish.org206-320-3542

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026